Stock Market Reviews

Read and share opinions on CLDI (Calidi Biotherapeutics, Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock ma

Latest News

• Calidi Biotherapeutics Presents New Data on its Therapeutic Lead, CLD-401, at the 2025 SITC Annual Meeting and Holds Its First Investor Day at SITC
  Nov 10, 2025
• Calidi Biotherapeutics Announces Investor Event to be Held on Friday, November 7th at the 2025 SITC Annual Meeting
  Nov 4, 2025
• Calidi Biotherapeutics Announces New Data to be Presented on its Therapeutic Lead, CLD-401, at the 2025 SITC Annual Meeting
  Oct 30, 2025
• Calidi Biotherapeutics Announces Establishment of Scientific Advisory Board to Support Development of CLD-401 and Advance its RedTail Platform for the Systemic Delivery of Targeted Genetic Medicine
  Oct 22, 2025
• Calidi Biotherapeutics to Present at the second annual Oncology Venture, Innovation, and Partnering Summit in Boston
  Sep 29, 2025
• Calidi Biotherapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
  Sep 2, 2025
• Calidi Biotherapeutics Announces Closing of $6.9 Million Underwritten Public Offering and Full Exercise of Underwriters’ Over-Allotment Option
  Aug 21, 2025
• Calidi Biotherapeutics Announces Pricing of $6 Million Underwritten Public Offering
  Aug 20, 2025
• Atossa Therapeutics and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
  Aug 1, 2025
• Calidi Biotherapeutics Receives FDA Fast Track Designation for CLD-201 (SuperNova), a First-In-Class Stem-Cell Loaded Viral Therapy for the Treatment of Patients with Soft Tissue Sarcoma
  Jul 29, 2025
• Calidi announces Reverse Stock Split, expected to begin trading on a 1-for-12 split adjusted basis on August 5, 2025
  Jul 25, 2025
• Join Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on July 24
  Jul 22, 2025
• Calidi Biotherapeutics Inc. (NYSE American: CLDI) Platform Designed to Transform Landscape of Cancer Treatment
  Jul 10, 2025
• Calidi Biotherapeutics to Raise $4.6 Million Through Warrant Exercise Agreement
  Jul 9, 2025
• Calidi Biotherapeutics Announces Exercise of Warrants for $4.6 Million of Gross Proceeds
  Jul 9, 2025
• Calidi Biotherapeutics Inc. (NYSE American: CLDI) Developing Precision Genetic Medicine Platform for Cancer Treatment
  Jul 8, 2025